



Guidelines Development Group
Biographies of proposed members

Guidance on offering long acting injectable cabotegravir as HIV prevention for people at substantial risk for HIV infection

14:00 to 17:00 CET on 9 March 2022

14:30 to 17:30 CET on 10 March 2022

Max Appenroth

GATE

Cologne, Germany

Max Appenroth (they/them, he/him) is a Germany-based trans activist, diversity consultant, and in the final year of their PhD at the Institute of Public Health at the Charité Universitätsmedizin Berlin, Germany. Max' research focuses on HIV prevention and care for trans and gender diverse people, especially for those on the transmasculine and non-binary spectrum. Max also works as the Research & Community Sexual Health Officer for the international trans-led organisation GATE - Global Action for Trans Equality. In this capacity they conduct key population research and coordinate the International Working Group of Transmasculine People & HIV. Max is an internationally recognized expert on HIV prevention and care in trans & gender diverse communities and provides support through their expertise for various different research projects.

With their own company 'diversity sparq' Max offers workshops & trainings to companies, institutions, and care facilities to learn (more) about sexual and gender diversity, and how to make workplaces and services more inclusive and accessible. Max wrote several research articles on healthcare and sexual health for trans communities and published the first book about trans healthcare in Germany.

Connie Celum

**International Clinical Research Center (ICRC), University of Washington
Seattle WA, United States of America**

Connie Celum, MD, MPH, is Professor of Global Health, Medicine, and Epidemiology and Director of the International Clinical Research Center and Center for AIDS Research at the University of Washington. She is an infectious disease physician, epidemiologist, and clinical investigator. Her research interests focus on HIV prevention strategies, including HIV pre-exposure prophylaxis and prevention and treatment of sexually-transmitted infections.



She co-led the Partners PrEP Study, which demonstrated high efficacy of tenofovir and emtricitabine-tenofovir (FTC-TDF) prophylaxis, which contributed to FDA approval of PrEP for HIV prevention. She has conducted research on implementation of oral PrEP among young African women, as well as a cross-over study of oral PrEP and dapivirine ring among adolescents and young African women. Dr Celum is part of the leadership of the IMPOWER 22 efficacy trial of monthly islatravir compared to daily FTC-TDF.

Mohamed Chakroun

Infectious Diseases Department, University Hospital of Monastir

Monastir, Tunisia

Mohamed Chakroun is a Medical Doctor, specialist in infectious diseases, full time work in the Hospital and Professor in the Faculty of Medicine of Monastir, Tunisia. He is a physician providing care and supporting people living with HIV (PLHIV) with an extensive experience in HIV care, antiretroviral therapy (ART) and prevention.

He is engaged with national AIDS program (NAP), community groups and health organizations in HIV care, HIV testing services, combination HIV prevention and policy development. He is also a national and regional expert on HIV/AIDS. He supported technically HIV/AIDS and STIs & Hepatitis (HAS) Unit in WHO Regional Office (Cairo, Egypt) in the areas of HIV testing, antiretroviral therapy and HIV combination prevention. He has been a member of WHO Guideline Development Groups since 2015 as well as a member of the WHO HIVResNet group.

Recently, He contributed to the working group for the implementation of PrEP in Tunisia, and He drafted a referential on the implementation of community-based PrEP in North African countries. He has written many national and regional manuals and guidelines on HIV/AIDS as well as several papers on HIV/AIDS in peer reviewed journals.

He has been the Chair of the Country Coordinating Mechanism (CCM) in Tunisia since 2014 and served as member of the Ethics and Governance Committee in the Global Fund for AIDS, Tuberculosis and Malaria since May 2018 as well as Alternate Board Member (ABM) for Eastern Mediterranean Region Constituency (EMRC) since March 2019.



Thato Chidarikire

National Department of Health

Pretoria, South Africa

Dr Thato Chidarikire is currently the Director for HIV Prevention Programmes in the National Department of Health in South Africa. She holds a PhD from The University of the Witwatersrand, specializing in Virology.

Her current portfolio includes the management of HIV prevention programmes including but not limited to HIV Testing Services (including HIV Self Testing: referred to as HIV Self Screening in SA), Pre-exposure Prophylaxis and Post-Exposure Prophylaxis programmes, the Condom Distribution and STI Programmes and the Youth and Key Populations HIV Prevention programmes.

Dr Chidarikire has over 20 years professional experience gained in Academia, Research, Parastatals, and the Public Health Sector. Her vast experience in health covers policy and guideline development, strategic and technical leadership of HIV and AIDS programmes and overseeing research and clinical trials.

In 2019 she served as co-chair for the WHO HTS Guideline Development Group, and she currently chairs the various national HIV Prevention Technical Working Groups and Think Tanks in South Africa. Dr Chidarikire has published in several peer reviewed journals and is currently the National Principal Investigator for the SA-CDC Co-Agreement.

Daouda Diouf

Enda Sante

Dakar, Senegal

Daouda Diouf is the Executive Director of ENDA Santé an international organization based in Dakar, Senegal that works in 12 countries in West and Central Africa region in the area of public health with a focus on country and regional programs focused HIV, adolescent and youth, maternal and child health, marginalized populations, sexual and reproductive health and human rights in Africa.

Mr Diouf is the CEO of the Civil Society Institute for HIV and Health in West and Central Africa, a platform of 140 NGO from 21 countries. Social economist and specialist in health and development programs, Mr Diouf plays leading role in African civil society networks on global health. In contributing to science, Mr Diouf is the author and co-author of several scientific articles and publication on HIV, key populations, sexual health, sustainable development in Africa.



Olga Denisiuk

Alliance for Public Health

Kiev, Ukraine

Olga Denisiuk, MD, DTMH, is the Head of Program Optimization and Research Team at Alliance for Public Health, Ukraine. Olga has 13 years' experience of work with HIV Programs. Her expertise is mostly focused on Key and Vulnerable Populations.

Involved in development, implementation and management of HIV testing, linkage to and retention in care strategies, including: intervention design, coordination with National and International stakeholders, field implementation, quality assurance and scale up. She is currently managing Programs which use Social Network Strategies (SNS) for HIV testing and community involving treatment strategies, like Optimized HIV Case Finding (OCF) and Community Initiated Treatment and Retention Interventions (CITI and CIRI) for more than 80 000 representatives of Key Populations in Ukraine

Provides technical support related to Programs for Key Populations in Eastern Europe and Central Asia, South-East Asia, Western Africa. Regional focal point for Structured Operational Research Training Initiative (SORT IT) by TDR, the Special Program for Research and Training in Tropical Diseases hosted at the WHO. Principal Investigator for studies related to Hepatitis C screening and point of care diagnostics. Principal Investigator for Demonstration Project on the Feasibility to Implement PrEP in MSM in Ukraine.

Inês Dourado

Instituto de Saúde Coletiva, Federal University of Bahia

Salvador, Brazil

Dr Inês Dourado –MD, MPH, Ph.D., full professor of epidemiology at the School of Public Health of the Federal University of Bahia, Brazil. She holds a master's degree in public health from the University of Massachusetts and a doctorate in epidemiology from the School of Public Health at the University of California at Los Angeles. Her main research area is on HIV/AIDS epidemiology and prevention. Together with colleagues from Brazil and abroad, she has coordinated and implemented internet, field survey, multicity Respondent Driven Sampling (RDS) surveys and other epidemiological studies on aspects of health, gender identity, and preventive behavior for HIV/IDS among key populations such as men who have sex with men (MSM), transgender women (TGW) and female sex workers.



Currently, Dr Dourado is the Protocol Chair and Salvador site PI for the Unitaid funded PrEP1519, a demonstration cohort study of the effectiveness of PrEP amongst adolescent MSM and TGW 15-19 years old in three Brazilian cities: Salvador, São Paulo, and Belo Horizonte. She was a visiting professor at New York University Master's Program in Public Health (2010-2011) and Brown University School of Public Health during the first semester of 2015 then an adjunct professor until June 2017.

Recently, she was elected to the Bahia State Academy of Sciences. Dr Dourado is the author/co-author of numerous articles in peer review journals, documenting her long-term commitment to the production/dissemination of knowledge, as well as contributing to improving the health and quality of life of people at increased risk for HIV/AIDS.

Elizabeth Irungu

Jhpiego

Nairobi, Kenya

Elizabeth Irungu, MBChB, MPH, PhD, is a Regional Technical Advisor at Jhpiego whose work focuses on oral PrEP implementation and introduction and scale up of new PrEP products in several countries in Africa. She is serving in a leadership role in the design and conduct of implementation science studies for new PrEP products under Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC), a USAID funded project.

Previously, Dr. Irungu was country director of the Partners Scale-Up Project, an implementation science project that introduced and scaled up oral PrEP for HIV sero-different couples integrated in public health facilities in Kenya. She worked on the Partners PrEP Study and the Partners Demonstration Study and has been an investigator on several studies evaluating innovative approaches for improving efficiency of PrEP service delivery. Elizabeth has extensive expertise in clinical work, conduct of clinical research and implementation science and sits on the PrEP Technical Working Group for the National AIDS and STD Control Program of Kenya. She trained as a medical doctor at the University of Nairobi in Kenya, and obtained both an MPH (Epidemiology) and a PhD (Implementation Science) from the University of Washington in Seattle.



Julie Fox

King's College

London, United Kingdom

Julie Fox is a HIV consultant at Guys and St Thomas'/Kings College London, United Kingdom. She leads HIV prevention programmes in HIV post exposure prophylaxis and Pre-Exposure Prophylaxis. This includes the CHAPS programme, which focuses on HIV prevention in young adults in sub-Saharan Africa: comprising mixed methods social science and a novel Pharmacokinetic/ Pharmacodynamic dose finding study for insertive sex. She is trial physician for PREPVACC- a combined HIV vaccine and PrEP efficacy trial also in sub-Saharan Africa. She is on United Kingdom guideline committees for PrEP, PEPSE and HIV treatment.

Andrew Grulich

Kirby Institute, University of New South Wales

Sydney, Australia

Professor Andrew Grulich is Director of the Populations and Prevention Theme and Head of the HIV Epidemiology and Prevention Program at the Kirby Institute, University of New South Wales, Sydney, Australia. He is a member of the Governing Council of the International AIDS Society, and a Fellow of the Australian Academy of Health and Medical Science.

Grulich is a leading researcher in the prevention of HIV and sexually transmitted infections in gay, bisexual and other men who have sex with men. He was Principal Investigator of the Opposites Attract study in Australia, Thailand and Brazil. The study demonstrated no HIV transmission within serodiscordant gay couples when the HIV positive partner had undetectable viral load, a result which became one of the cornerstones of the Undetectable equals Untransmissible campaign. He was Principal Investigator of the EPIC-NSW PrEP implementation study, one of the world's largest PrEP implementation studies, and one of the first to demonstrate real-world impact on HIV notification rates. His group is currently conducting foundational research to pave the way for introduction of long acting injectable PrEP and is working with groups in South-East Asia to pave the way for PrEP introduction in key affected populations in that region.



Diane Havlir

University of California

San Francisco, United States of America

Diane Havlir, MD is a UCSF Professor and Chief of the HIV, Infectious Diseases and Global Medicine Division at ZSFG, home to world-renowned HIV research and Ward 86 clinical program. She is also the Associate Chair of Clinical Research in the Department of Medicine and Principal Investigator of the Sustainable East Africa Research in Community Health (SEARCH) Study and Interim-Director of the UCSF AIDS Research Institute (ARI).

The overall goal of her research is to develop therapeutic and prevention strategies to respond to global infectious disease pandemics: HIV, TB, and COVID-19. Antiretroviral therapy (for prevention or treatment) is one of the greatest successes in medicine, yet we have not fully used it to eliminate HIV or tuberculosis (TB). In the SEARCH study, Dr. Havlir and her team showed that a multi-disease, patient-centered approach to HIV testing and treatment reduced HIV incidence, HIV-associated tuberculosis and HIV-associated mortality, while improving population-level control of hypertension in a NIH-funded 320,000 person cluster-randomized study in rural East Africa. She continues towards her goal to accelerate the end of AIDS through the SEARCH-Sapphire study, which tests innovative prevention and treatment strategies intended to reach vulnerable populations left behind by current approaches. The study team is currently testing a multi-disease and multi-sector approach, on a path to universal healthcare.

Phan Thi Thu Huong

Viet Nam Authority of HIV/AIDS Control

Hanoi, Vietnam

Assistant Professor Phan Thi Thu Huong, MD. PhD - Deputy Director General of Vietnam Authority of HIV/AIDS Control has been working for Viet Nam HIV/AIDS program more than 26 years. Her expertise includes HIV treatment and care, HIV counselling and testing, laboratory quality management, health system strengthening, HIV surveillance and monitoring.

Since 2011, Assistant Professor Dr Phan Thi Thu Huong has also been appointed to be Vice President of Preventive Medicine Association and member of Boards of Editors of Preventive Medicine Journal. From April 2017, she has been appointed to be Vietnam Coordinator of French Agency for Research on AIDS and Viral Hepatitis (ANRS – France Recherche Nord & Sud Sida-Hiv Hépatites). Regarding teaching career, Dr Huong is now participating in giving lectures in Hanoi Medical University, Hanoi University of Public Health and Nam Dinh Nursing School.



Dr Phan Thi Thu Huong obtained her PhD. Degree in 2013 and Associate Professor in Health in 2017. She has participated in and contributed to more than 120 researches & publications. Among those, there are over 40 researches published in international journals. She also participated in editor board & or editor in chief of 16 Vietnamese books/guidelines in related fields. Besides scientific research, Dr Huong has been participating in teaching in different Universities and supervising/mentoring graduate and PhD students. Up to now, there are 2 PhD and more than 15 master students being mentored and graduated under her supervision. Her most recent contribution are National Training Curriculum in HIV Care & Treatment; and National Training Curriculum in PrEP. Dr Phan Thi Thu Huong has been leading Viet Nam National PrEP program from very early stage of piloting to national wide implementation. Between 2018-2021, PrEP clients in Vietnam has risen to nearly 40,000 people which contribution significantly on reducing new HIV infections especially among MSM population.

Rena Janamnuaysook

Institute of HIV Research and Innovation (IHRI)

Bangkok, Thailand

Rena Janamnuaysook works as a Program Manager for Implementation Science at the Institute of HIV Research and Innovation (IHRI) in Bangkok, Thailand, where she established the Tangerine Community Health Clinic as the first transgender-led health clinic in the region. She manages and provides technical guidance for the development and implementation of HIV research and programs for key populations in Thailand and in Asia.

Rena is one of the program fellows of the NIH CHIMERA D43 program which is part of the IeDEA network program to learn to conduct the HIV and mental health implementation research. She has also worked as Project Management Specialist in HIV Key Populations for the US Agency for International Development and was a co-founder of the Thai Transgender Alliance, the first transgender-owned human rights organization in Thailand. Rena received a master degree in international development from the University of Birmingham, United Kingdom and is currently doing her PhD at Amsterdam Institute for Global Health and Development, University of Amsterdam, the Netherlands.



Mehdi Karkouri

ALCS/Centre Hospitalier Universitaire Ibn

Casablanca, Morocco

Mehdi Karkouri is a Professor of Medicine and the president of ALCS, Association de Lutte Contre le Sida (“The Moroccan NGO to fight AIDS”), a Community-based organization established in 1988. Dr Karkouri has been more particularly involved in the HIV Testing and Counseling activities, research and training, and is the resource person for anti-Stigma and Discrimination policy. He has also been involved in the MENA Region, having undertaken missions in several countries of the Region and acted as consultant for various international organizations, such as WHO, UNICEF, and the European Commission. He has been member of WHO guidelines development groups on HIV Testing Services and Key populations.

ALCS is a running, on behalf of the Moroccan Ministry of Health, a PrEP program, based on a community model. The program has started with a pilot in 2018 and is now part of the routine offer of combined prevention, with more than 700 active PrEP users.

Geoffroy Liegeon

University of Paris Diderot

Paris, France

Dr Geoffroy Liegeon is an assistant professor of infectious diseases at Paris University, and works as a clinician in the infectious diseases department at the Saint-Louis Hospital in Paris. With a background in nephrology, his first research works were dedicated to the renal toxicity of tenofovir in different populations including HIV-infected patients, HBV-infected pregnant women, and PrEP users. Geoffroy has notably coordinated in Thailand an NIH-funded project aiming to assess the risk of tubular dysfunction in pregnant women receiving TDF for the prevention of mother to child transmission of HBV. As part of the ANRS-Ipergay and Prevenir study groups, he studied the potential benefit in terms of renal safety of the “on-demand” dosing for HIV PrEP. He also developed a specific interest for HIV prevention studies aiming to increase PrEP adherence, uptake, and persistence. Geoffroy leads an ANRS-funding clinical trial aiming to assess a simplified on-demand HIV PrEP regimen for MSM. He also coordinates a study assessing the acceptability and persistence on HIV PrEP in MSM switching from oral TDF/FTC to long-acting injectable cabotegravir in the ANRS- Prevenir cohort.



Imelda Mahaka

Pangaea Zimbabwe AIDS Trust

Harare, Zimbabwe

Imelda Mahaka (BSW) is the Executive Director with Pangaea Zimbabwe AIDS Trust (PZAT). She has strong advocacy and stakeholder engagement experience, working in conjunction with international, regional and local organizations to strengthen demand, uptake and quality of HIV prevention, care and treatment and services. She has vast experience implementing and coordinating socio behavioral HIV research activities focusing on adolescent girls and young women including key populations. In the past decade, she has also been working around policy advocacy and service delivery with community-based HIV prevention programs and adapting public health intervention models to be more culturally appropriate for low resourced communities.

Kenneth Mayer

Fenway Health Centre

Boston, United States of America

Dr Kenneth Mayer trained in Internal Medicine at Beth Israel Hospital and in Infectious Diseases and Molecular Epidemiology at Brigham and Women's Hospital and was a clinical and research fellow at Harvard during that time. As the founding Medical Research Director of Fenway Health, he created a community health research program that has developed an international reputation for its capability to conduct community-based research. He is currently a Professor of Medicine at Harvard Medical School, a Professor in Global Health and Population at the Harvard TC Chan School of Public Health and Attending Physician at Beth Israel Deaconess Medical Center.

Starting in 1994, he has been a site Principal Investigator of NIH-funded clinical trials units, focusing on bio-behavioral HIV prevention research, and is a member of the scientific leadership of HPTN. He has co-authored more than 1000 peer-reviewed publications, co-authored the first text on AIDS for the general public and has co-edited 5 academic texts. He has served on the national boards of amfAR, HIVMA, and GLMA, was a member of the CDC/HRSA HIV/AIDS Advisory Committee, and was a member of the Governing Council of the International AIDS Society. He is an Editor-in-Chief of the Journal of the International AIDS Society, and serves on the PEPFAR Scientific Advisory Board.



Getrude Ncube

Ministry of Health and Child Care

Harare, Zimbabwe

Getrude Ncube is a Public Health Practitioner and an HIV Prevention Leader with a master's degree in international health and 19 over years of professional experience in HIV/AIDS Prevention, Treatment, Care, and Support strategies in Zimbabwe and beyond. She has a wealth of experience working across all levels of the Zimbabwe health system through a career spanning 35 years in the health sector. Getrude has extensive experience in policy and program development and implementation, including providing technical support in program planning and implementation nationally and supporting other countries. Her experience also includes supporting National and Subnational units on HIV Prevention, Care, and Treatment programming, including policies, strategies, plans, and resource mobilization. Regarding knowledge management, she also provided technical inputs in the documentation of best practices on HIV Prevention, Treatment, and Care and supported sharing those practices at National, Regional and International levels in varied audiences, addressing both technical and policy issues. Getrude has demonstrated the ability to produce results over the years and have also fostered integration and teamwork in Zimbabwe HIV prevention space.

Technical expertise: Getrude provides leadership, guidance, and technical support for Zimbabwe's full range of comprehensive HIV prevention strategies (HIV testing Services including HIV Self testing, Voluntary Medical Male Circumcision, STI screening and condom programming, Key Populations Programming, Pre-Exposure Prophylaxis (PrEP) and was the focal person in PrEP demonstration projects in Zimbabwe that informed the scale up of PrEP for the populations at substantial risk of getting HIV. She oversees the development and rollout of appropriate evidence-informed HIV prevention policies, guidelines, and manuals used to support program training and implementation across all levels of the health system and all districts in Zimbabwe. She leads the MoHCC's engagement with the communities, traditional leaders, development partners, and the donor community on all HIV prevention interventions in Zimbabwe. Global: Getrude has participated in the WHO Guideline Development for HIV Testing Services as well as HIV Self Testing. Participated in the STAR research pilot for Zimbabwe and was the focal person for STAR Research Project for Zimbabwe.



Urvi Parikh

University of Pittsburgh

Pittsburgh, United States of America

Urvi M Parikh, PhD is an Associate Professor of Medicine at the University of Pittsburgh School of Medicine, Division of Infectious Diseases. Her research focuses on examining the risk of HIV-1 drug resistance with the use of antiretrovirals for HIV prevention. She is the Associate Director of the AIDS Clinical Trial Group (ACTG) Virology Specialty Lab and HIV Drug Resistance Technical Lead of the Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) project. For the past 14 years, she was also the Associate Director of the Microbicide Trials Network (MTN) Virology Core, and served as virologist for studies evaluating the safety and efficacy of candidate antiretroviral products for HIV prevention. Her laboratory conducts sensitive assays to genotype and phenotype HIV-1 and preclinical research towards the development of new agents for HIV prevention.

Danvic Rosadino

LoveYourself Inc.

Manila, Philippines

Danvic is the Program and Innovations Director of LoveYourself Inc., a community-based organization based in metropolitan Manila, Philippines. While the organization's main thrust is to promote self-worth leading to self-care among the men who have sex with men (MSM) and the youth, the organization is mostly known to provide HIV and sexual health-related services to the community.

He has spearheaded various HIV and sexual health researches, programs, and innovations, such as Project PrEPPY (PrEP Pilipinas; a multi-sectoral program that spearheaded the introduction of HIV pre-exposure prophylaxis in the Philippines), and SelfCare (introduction of HIV unassisted self-testing in the Philippines). He also conducted several researches on HIV prevalence and incidence (in the Philippines and Malaysia), and values and preferences studies on Hepatitis C self-testing and COVID-19 self-testing (as part of a multi-country research). He has also provided consultations and workshops on HIV PrEP demand generation in several countries in Asia.

Juggling his passion for learning and being an HIV advocate, he also headed the learning and development team of LoveYourself. He is also an HIV counselor, life coach, and client data protection officer. Formerly, he was a Surveillance Assistant at the National HIV and STI Surveillance and Strategic Information Unit of the Epidemiology Bureau, Department of Health – Philippines.



Danvic is currently taking Masters of International Health at the Faculty of Management and Development Studies of the University of the Philippines – Open University. He finished his Bachelor of Science in Biology degree at the College of Science of the University of Santo Tomas, in Manila, Philippines in 2010.

François Venter

University of the Witwatersrand

Johannesburg, South Africa

Professor WD François Venter, MD, FCP, PhD is the Divisional Director of Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training. He has an active interest in public sector access to HIV services, and his work involves health systems research that directly translates into national programmes, most recently involving dolutegravir and TAF. He leads multiple antiretroviral treatment optimisation studies and is currently working on new first and second-line antiretroviral options, patient linkage-to-care interventions, and self-testing projects. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on different populations such as men, women, children, young people, truckers, sex workers and LGBTI.

For the last 20 years, he has been an advisor to bodies such as the South African government, Southern African HIV Clinicians Society, UNAIDS, and WHO, including contributing to international, regional, and national HIV guidelines. He has been involved in several human rights cases involving HIV within the Southern African region and has an active interest in medical ethics.

Mitchell Warren

AVAC

New York, United States of America

Since 2004, Mitchell Warren has been Executive Director of AVAC, an international non-governmental organization that uses education, policy analysis, advocacy, communications and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options.

Previously, he served as Senior Director for Vaccine Preparedness at the International AIDS Vaccine Initiative (IAVI) focusing on increasing community understanding and national involvement in AIDS vaccine development; Vice President of International Affairs for The Female Health Company (FHC), manufacturer of the female condom, where he directed efforts



to design and implement reproductive health programs and led global advocacy efforts for female-initiated prevention methods; and six years at Population Services International (PSI) designing and implementing social marketing, communications and health promotion activities, including five years running PSI's project in South Africa.

Warren is president of the TB Alliance Stakeholders Association; co-chair of the Global Prevention Coalition; member of the President's Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board (SAB); and board member of the Towards an HIV Cure Initiative of the International AIDS Society (IAS). He is also past president of the Global HIV Vaccine Enterprise. In 2013, he helped establish the biennial HIV Research for Prevention conference and is one of the co-chairs for R4P 2021. Warren has degrees in English and History from the University of Wisconsin-Madison and studied health policy at the Johns Hopkins University School of Hygiene and Public Health.